Novo Nordisk provides a development update on two new investigational drugs for the bleeding disorders community.
The company’s ultra fastacting recombinant factor VIIa is progressing to a phase 3 trial after the successful completion of a phase 2 safety, pharmacokinetics and efficacy trial; the phase 3 trial is currently being designed. A phase 3 trial for the factor XIII drug was recently been completed and showed that, compared to a historic […]